Chief Financial Officer
Andreas Emmenegger is Chief Financial Officer (CFO) and Co-Entrepreneur of Molecular Partners since 2007. Prior to that, he was CFO of Glycart Biotechnology AG where he had a leading role in the successful CHF 235 million trade sale to F. Hoffmann-La Roche AG in 2005. Andreas was Head of Strategic Alliance Finance (Genentech) for Roche Headquarters, Basel, Switzerland. He has more than 15 years of experience as a CFO of several public and private multinational companies raising more than CHF 400 million equity through public and private offerings, including the lead in the successful IPOs at the SIX Swiss Exchange of Molecular Partners in 2014 and of Interroll Holding AG in 1997. In addition, Andreas has more than 10 years of international industry experience in banking, capital markets, Mergers & Acquisitions and human resources. He is also co-founder and member of the board of directors of Piqur Therapeutics AG, Switzerland, a venture-backed privately held biopharmaceutical company. Andreas holds a degree in finance, economics and business administration as well as an Executive MBA degree from IESE Business School, Barcelona.